Johannes Schetelig
Distinguished in Chronic B-Cell Leukemia (CBCL)

Johannes Schetelig

Dresden, SN, DE 
Distinguished in Chronic B-Cell Leukemia (CBCL)
Dresden, SN, DE 
OverviewLocationsClinical Research

Overview

Johannes Schetelig practices in Dresden, Germany. Mr. Schetelig is rated as a Distinguished expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Leukemia, Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Bone Marrow Transplant, and Bone Graft.

His clinical research consists of co-authoring 230 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 30 articles in the study of Chronic B-Cell Leukemia (CBCL).

Gender
Male

Locations

Dresden, SN, Germany
Other Locations
Tuebingen, BW, Germany
39063, Germany
Marburg An Der Lahn, HE, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Graft vs Host Disease Prophylaxis in Unrelated Donor Transplantation: a Randomized Clinical Trial Comparing PTCY vs ATG (GRAPPA)
Graft vs Host Disease Prophylaxis in Unrelated Donor Transplantation: a Randomized Clinical Trial Comparing PTCY vs ATG (GRAPPA)
Enrollment Status: Active_not_recruiting
Publish Date: December 20, 2024
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, ATG
Study Phase: Phase 3
Randomized Phase III Study Comparing Conventional Chemotherapy to Low Dose Total Body Irradiation-Based Conditioning and HCT From Related and Unrelated Donors as Consolidation Therapy for Older Patients With AML in 1st Complete Remission
Randomized Phase III Study Comparing Conventional Chemotherapy to Low Dose Total Body Irradiation-Based Conditioning and HCT From Related and Unrelated Donors as Consolidation Therapy for Older Patients With AML in 1st Complete Remission
Enrollment Status: Terminated
Publish Date: October 14, 2021
Intervention Type: Drug, Procedure
Study Phase: Phase 3
View 1 Less Clinical Trial

230 Total Publications

Prognostic Value of Multicolor-Flow Cytometric Measurable Residual Disease Detection in Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation: Potential Role of HLA-DR.
Prognostic Value of Multicolor-Flow Cytometric Measurable Residual Disease Detection in Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation: Potential Role of HLA-DR.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schetelig's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile